Every material Form 8-K Pfizer has filed with the SEC since November 13, 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pfizer's board unanimously elected Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026, after she served as interim CFO since August 16, 2026. The filing sets her base salary at $1,300,000 and her target annual cash incentive at $1,300,000, and it does not report any financial results or change to guidance.
Cecile Guegan appointed CFO and Executive Vice President, effective November 1, 2026; interim CFO since August 16, 2026
Annual base salary of $1,300,000
Annual target cash incentive of $1,300,000, equal to 100% of base salary
She will oversee all corporate finance functions, including audit, treasury, investor relations and tax
Pfizer announced third-quarter 2026 revenues of $16.6 billion, matching the prior-year period operationally, while reporting adjusted diluted EPS of $0.87. Driven by solid performance in non-COVID and newly launched products, the company raised its full-year 2026 revenue guidance to a range of $62.0 to $64.0 billion and narrowed its adjusted diluted EPS guidance to $2.95 to $3.05. Shareholders also saw the appointment of Cecile Guegan as Chief Financial Officer and Executive Vice President.
Pfizer reported second-quarter 2026 revenue of $15.0 billion, up 3% from a year earlier, and a reported loss of $0.04 per share, which reflects $4.3 billion in non-cash intangible asset impairments. Adjusted diluted EPS was $0.77, compared with $0.78 a year earlier. Pfizer raised its full-year 2026 revenue guidance midpoint by $500 million to a range of $60.5 to $62.5 billion and reaffirmed adjusted EPS guidance of $2.80 to $3.00, which absorbs an expected impact of about $0.10 from the Innovent Biologics transaction.
Q2 2026 revenue was $15.0 billion, up 3% reported and 1% operationally; reported loss per share was $(0.04) versus EPS of $0.51 a year earlier.
Full-year 2026 revenue guidance raised to $60.5 to $62.5 billion; adjusted diluted EPS guidance reaffirmed at $2.80 to $3.00.
Pfizer announced $2.5 billion of additional anticipated productivity savings, expected to be realized from 2027 through 2029.
Pfizer is not planning share repurchases in 2026; $3.3 billion remains under its existing authorization.
Pfizer said on June 18, 2026 that it is reaffirming all components of its full-year 2026 guidance, following its announcement of a Chief Financial Officer transition the same day. The guidance includes revenues of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, unchanged from the December 16, 2025 guidance and the May 5, 2026 reaffirmation.
Full-year 2026 revenue guidance reaffirmed at $59.5 billion to $62.5 billion
Adjusted diluted EPS guidance reaffirmed at $2.80 to $3.00
Guidance first issued December 16, 2025 and reaffirmed May 5, 2026 on the first quarter earnings call
Filing follows a Chief Financial Officer transition announcement made June 18, 2026
Pfizer said Chief Financial Officer Dave Denton will leave the company on August 15, 2026 to take a consumer goods role outside the pharmaceutical industry. The company said the departure is not related to its financial or operating results. Cecile Guegan, a Pfizer finance executive since 2005, will serve as interim CFO from August 16 while Pfizer searches for a permanent successor.
Dave Denton notified Pfizer on June 16, 2026 that he will step down as CFO effective August 15, 2026
Cecile Guegan, Senior Vice President, Finance, Global Biopharmaceutical Business, becomes Interim CFO effective August 16, 2026
Pfizer is conducting a comprehensive internal and external search for a permanent successor
Chairman and CEO Albert Bourla credited Denton with leading transactions including Seagen, Biohaven and Metsera
Pfizer reported first-quarter 2026 revenue of $14.5 billion, up 5% from a year earlier (2% on an operational basis). Adjusted diluted EPS fell 18% to $0.75 and reported diluted EPS fell 10% to $0.47. The company reaffirmed its full-year 2026 guidance of $59.5 to $62.5 billion in revenue and $2.80 to $3.00 in adjusted diluted EPS, so shareholders get a steady outlook alongside lower first-quarter profit.
Revenue was $14.5 billion, up 5% reported and 2% operationally; excluding Comirnaty and Paxlovid, revenue grew 7% operationally.
Reported net income attributable to Pfizer shareholders was $2,687 million, down 9% from $2,967 million a year earlier.
Full-year 2026 guidance was reaffirmed: revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00; guidance assumes no share repurchases in 2026.
Pfizer paid $2.4 billion in cash dividends, or $0.43 per share, during the first three months of 2026.
Pfizer reported fourth-quarter 2025 revenues of $17.6 billion, down 1% from a year earlier, and a net loss of $1.6 billion, or $(0.29) per share, after $4.4 billion in non-cash intangible asset impairment charges. Adjusted diluted EPS rose 5% to $0.66, and the company reaffirmed its full-year 2026 guidance of $59.5 to $62.5 billion in revenue and $2.80 to $3.00 in adjusted diluted EPS, which excludes share repurchases.
Q4 2025 revenues $17.6 billion, down 1% reported and down 3% operationally; down 2% for full year 2025 to $62.6 billion
Q4 2025 reported net loss of $1.6 billion, or $(0.29) per share, versus net income of $410 million, or $0.07 per share, a year earlier
Q4 2025 adjusted diluted EPS $0.66 versus $0.63; full-year 2025 adjusted diluted EPS $3.22 versus $3.11
2026 guidance reaffirmed; no share repurchases expected in 2026, and $3.3 billion remains under the existing authorization
Pfizer lowered its full-year 2025 revenue guidance to approximately $62.0 billion from $61.0 to $64.0 billion, while reaffirming its 2025 adjusted diluted EPS guidance of $3.00 to $3.15. The company also issued 2026 guidance calling for revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, below the 2025 EPS range, citing a higher expected tax rate and about $1.5 billion of revenue loss from loss of exclusivity.
2025 revenue guidance revised to approximately $62.0 billion from $61.0 to $64.0 billion; 2025 adjusted diluted EPS guidance of $3.00 to $3.15 reaffirmed
2026 adjusted diluted EPS guidance of $2.80 to $3.00, with an effective tax rate of approximately 15% versus approximately 11% in 2025
2026 revenue guidance of $59.5 to $62.5 billion includes about $1.5 billion lower COVID-19 product revenue and about $1.5 billion negative impact from loss of exclusivity
2026 adjusted SI&A and R&D expenses combined expected at $23.0 to $25.0 billion; guidance assumes no share repurchases in 2025 or 2026
Pfizer completed a public offering of seven series of notes with total principal of $6.0 billion, due between 2027 and 2065. The notes were issued under an indenture with The Bank of New York Mellon as trustee, and the underwriting agreement was dated November 18, 2025. The filing reports the terms of the debt but does not state how Pfizer plans to use the proceeds.
Seven series: floating rate notes due 2027 ($500 million), 3.875% notes due 2027 ($1.0 billion), 4.200% notes due 2030 ($1.0 billion), 4.500% notes due 2032 ($1.25 billion), 4.875% notes due 2035 ($1.25 billion), 5.600% notes due 2055 ($500
Notes were issued under the Sixth Supplemental Indenture dated November 21, 2025, with The Bank of New York Mellon as trustee
Underwriting and pricing agreements dated November 18, 2025, with Citigroup Global Markets, Deutsche Bank Securities, J.P. Morgan Securities and Mizuho Securities USA as representatives
Pfizer said on November 13, 2025 that it completed its acquisition of Metsera, Inc. under a merger agreement dated September 21, 2025, as amended November 7, 2025. Metsera holders receive $65.60 per share in cash at closing, an enterprise value of approximately $7.0 billion, plus contingent value rights worth up to $20.65 per share tied to three milestones. The deal adds Metsera's GLP-1-based weight-loss drug candidates to Pfizer's pipeline, but the milestone payments depend on future clinical and regulatory events.
Closing cash consideration of $65.60 per Metsera share, an enterprise value of approximately $7.0 billion
Contingent value rights of up to $20.65 per share in cash across three milestones
Milestones: $4.60 on Phase 3 trial start for MET-097i+MET-233i; $6.40 on FDA approval of MET-097i monotherapy; $9.65 on FDA approval of the combination
Deal completed November 13, 2025 via Mayfair Merger Sub, Inc., a wholly owned subsidiary
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Pfizer filing is on SEC EDGAR ↗. 8-K briefs of other companies →